Which statement best describes DS-3790, the novel antibody-drug conjugate discussed in this first-in-human study in non-Hodgkin lymphoma?
A CD19-directed ADC carrying a microtubule inhibitor (MMAE) payload, already approved in diffuse large B-cell lymphoma
A CD37-directed ADC carrying a DXd topoisomerase I inhibitor payload, which is established in solid tumors and being brought into hematologic malignancies for the first time
A CD37-directed bispecific antibody that engages T-cells, with no cytotoxic payload